Quarterly ResultMay 7, 2026, 07:37 AM
Rapport Therapeutics Q1 Net Loss Narrows to $19.9M; Revenue $20M
AI Summary
Rapport Therapeutics reported a reduced net loss of $19.9 million for the first quarter of 2026, a significant improvement from the $24.1 million loss in the same period last year. This was primarily driven by the recognition of $20 million in collaboration revenue, which was absent in the prior year. The company ended the quarter with $476.8 million in cash, cash equivalents, and short-term investments, which is expected to fund operations for at least the next 12 months, though additional financing will be required for its growth strategy.
Key Highlights
- Net loss narrowed to $19.9 million in Q1 2026 from $24.1 million in Q1 2025.
- Collaboration revenue was $20 million in Q1 2026, up from $0 in Q1 2025.
- Cash and cash equivalents increased to $78.1 million as of March 31, 2026.
- Total cash, cash equivalents, and short-term investments were $476.8 million.
- Research and development expenses rose to $32.7 million from $19.6 million year-over-year.
- Net cash used in operating activities decreased to $13.1 million from $20.2 million.
- Accumulated deficit reached $255.1 million as of March 31, 2026.